Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
Ono Pharmaceutical’s immuno-oncology star Opdivo (nivolumab) saw its sales dwindle 13% to 90.1 billion yen in the year ended March 2018, despite a 45% volume increase, as it took a full-year blow from a 50% emergency price slashed imposed in…
To read the full story
Related Article
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
- Opdivo’s Half-Year Sales Sag as 50% Price Cut Takes Toll: Ono
November 7, 2017
- Ono Lifts Half-Year Guidance on Opdivo Boon
October 27, 2017
- Opdivo Drives Ono to Record Profits in FY2016
May 15, 2017
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…